2012

Fresenius to discontinue biotech subsidiary

Friday, December 14, 2012

Fresenius, a health care group with international operations, has decided to discontinue its subsidiary Fresenius Biotech. Instead, the company will focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which offer significant growth opportunities.

[Read More]

Biocartis completes $44.5M series D funding

Friday, December 14, 2012

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

[Read More]

Eisai, UCL form drug discovery alliance for neurological diseases

Friday, December 14, 2012

Eisai, a pharmaceutical company based in Toyko, and University College London (UCL) have entered into a new agreement to establish a major drug discovery and development collaboration investigating new ways of treating neurological diseases such as Alzheimer’s disease, Parkinson’s disease and other related disorders.

[Read More]